FDA Inspection 1230049 — Novitium Pharma LLC
The FDA completed an inspection of Novitium Pharma LLC on February 16, 2024 in East Windsor, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 16, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- East Windsor, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)